{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T21:11:29Z","timestamp":1786569089309,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jcyt.2023.01.007","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T17:37:04Z","timestamp":1676050624000},"page":"659-669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical outcomes of therapeutic leukapheresis in acute promyelocytic leukemia: A single-center retrospective cohort study"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4168-5187","authenticated-orcid":false,"given":"Howon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Sik","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Wook","family":"Jekarl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.jcyt.2023.01.007_bib0001","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1182\/blood-2014-10-551507","article-title":"How I treat hyperleukocytosis in acute myeloid leukemia","volume":"125","author":"R\u00f6llig","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2023.01.007_bib0002","doi-asserted-by":"crossref","first-page":"11935","DOI":"10.1038\/s41598-019-47937-4","article-title":"Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia","volume":"9","author":"Yoon","year":"2019","journal-title":"Scientific reports"},{"issue":"1","key":"10.1016\/j.jcyt.2023.01.007_bib0003","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3324\/haematol.2011.046490","article-title":"Treatment advances have not improved the early death rate in acute promyelocytic leukemia","volume":"97","author":"McClellan","year":"2012","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.jcyt.2023.01.007_bib0004","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.leukres.2013.05.007","article-title":"Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death","volume":"37","author":"Altman","year":"2013","journal-title":"Leukemia Research"},{"issue":"5","key":"10.1016\/j.jcyt.2023.01.007_bib0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bjh.13189","article-title":"Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis","volume":"168","author":"Daver","year":"2015","journal-title":"British journal of haematology"},{"issue":"51","key":"10.1016\/j.jcyt.2023.01.007_bib0006","doi-asserted-by":"crossref","first-page":"e9324","DOI":"10.1097\/MD.0000000000009324","article-title":"Analysis of early death in newly diagnosed acute promyelocytic leukemia patients","volume":"96","author":"Xu","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.jcyt.2023.01.007_bib0007","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/leu.2017.71","article-title":"Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013","volume":"31","author":"Lehmann","year":"2017","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.jcyt.2023.01.007_bib0008","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/bloodadvances.2021004789","article-title":"Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study","volume":"5","author":"Gill","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jcyt.2023.01.007_bib0009","first-page":"1247","volume":"96","author":"Sanz","year":"2000","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jcyt.2023.01.007_bib0010","first-page":"1750","article-title":"Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia","volume":"8","author":"Dubois","year":"1994","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jcyt.2023.01.007_bib0011","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1182\/blood.V84.11.3843.bloodjournal84113843","article-title":"Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN\/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid","volume":"84","author":"Vahdat","year":"1994","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2023.01.007_bib0012","first-page":"90","article-title":"Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome","volume":"95","author":"Tallman","year":"2000","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jcyt.2023.01.007_bib0013","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.2000.18.13.2620","article-title":"Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide","volume":"18","author":"Camacho","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.jcyt.2023.01.007_bib0014","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bcmd.2010.12.001","article-title":"Don't just stand there, do something: Strategies for the prevention of early death in acute promyelocytic leukemia: A commentary","volume":"46","author":"Tallman","year":"2011","journal-title":"Blood Cells, Molecules, and Diseases"},{"issue":"3","key":"10.1016\/j.jcyt.2023.01.007_bib0015","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3324\/haematol.2021.279052","article-title":"Timely diagnosis and treatment of acute promyelocytic leukemia should be available to all","volume":"107","author":"Schuh","year":"2021","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.jcyt.2023.01.007_bib0016","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","article-title":"Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"113","author":"Sanz","year":"2009","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.jcyt.2023.01.007_bib0017","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jcyt.2023.01.007_bib0018","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","article-title":"Acute promyelocytic leukemia current treatment algorithms","volume":"11","author":"Yilmaz","year":"2021","journal-title":"Blood Cancer Journal"},{"issue":"6","key":"10.1016\/j.jcyt.2023.01.007_bib0019","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1600-0609.2005.00421.x","article-title":"Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome","volume":"74","author":"Novotny","year":"2005","journal-title":"European Journal of Haematology"},{"issue":"4","key":"10.1016\/j.jcyt.2023.01.007_bib0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000341805","article-title":"Leukocyte depletion by therapeutic leukocytapheresis in patients with leukemia","volume":"39","author":"H\u00f6lig","year":"2012","journal-title":"Transfusion medicine and hemotherapy: offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie"},{"issue":"4","key":"10.1016\/j.jcyt.2023.01.007_bib0021","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7326\/0003-4819-117-4-292","article-title":"The retinoic acid syndrome\" in acute promyelocytic leukemia","volume":"117","author":"Frankel","year":"1992","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1016\/j.jcyt.2023.01.007_bib0022","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2023.01.007_bib0023","doi-asserted-by":"crossref","first-page":"6426","DOI":"10.1038\/s41598-021-85918-8","article-title":"The factors influencing clinical outcomes after leukapheresis in acute leukaemia","volume":"11","author":"Lee","year":"2021","journal-title":"Scientific reports"},{"issue":"2","key":"10.1016\/j.jcyt.2023.01.007_bib0024","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1172\/JCI107191","article-title":"Rheology of leukocytes, leukocyte suspensions, and blood in leukemia. Possible relationship to clinical manifestations","volume":"52","author":"Lichtman","year":"1973","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.jcyt.2023.01.007_bib0025","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood.V60.2.279.279","article-title":"Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations","volume":"60","author":"Lichtman","year":"1982","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jcyt.2023.01.007_bib0026","first-page":"1037","article-title":"Leukapheresis induced changes in cell cycle distribution and nucleoside transporters in patients with untreated acute myeloid leukemia","volume":"5","author":"Powell","year":"1991","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.jcyt.2023.01.007_bib0027","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s002770000162","article-title":"Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis","volume":"79","author":"Thi\u00e9baut","year":"2000","journal-title":"Annals of Hematology"},{"issue":"4","key":"10.1016\/j.jcyt.2023.01.007_bib0028","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/1097-0142(19870215)59:4<748::AID-CNCR2820590414>3.0.CO;2-E","article-title":"Tissue factor activity in leukemia cells. Special reference to disseminated intravascular coagulation","volume":"59","author":"Andoh","year":"1987","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jcyt.2023.01.007_bib0029","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00277-013-1676-6","article-title":"Increased promyelocytic-derived microparticles: a novel potential factor for coagulopathy in acute promyelocytic leukemia","volume":"92","author":"Ma","year":"2013","journal-title":"Annals of Hematology"},{"issue":"21","key":"10.1016\/j.jcyt.2023.01.007_bib0030","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1182\/blood.V122.21.3620.3620","article-title":"Thrombin generation and fibrinolytic activity in microparticles in acute promyelocytic leukemia","volume":"122","author":"Kwaan","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jcyt.2023.01.007_bib0031","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1182\/blood.V71.4.870.870","article-title":"A New Procoagulant in Acute Leukemia","volume":"71","author":"Falanga","year":"1988","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jcyt.2023.01.007_bib0032","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJM199904013401303","article-title":"Annexin II and bleeding in acute promyelocytic leukemia","volume":"340","author":"Menell","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"23","key":"10.1016\/j.jcyt.2023.01.007_bib0033","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.V126.23.2278.2278","article-title":"Tissue factor pathway inhibitor (TFPI) may be another important factor in the coagulopathy in acute promyelocytic leukemia (APL)","volume":"126","author":"Bassi","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2023.01.007_bib0034","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.1988.tb02432.x","article-title":"Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia","volume":"70","author":"Avvisati","year":"1988","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.jcyt.2023.01.007_bib0035","doi-asserted-by":"crossref","unstructured":"Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice \u2013 Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. 2019;34(3):171-354.","DOI":"10.1002\/jca.21705"},{"issue":"7","key":"10.1016\/j.jcyt.2023.01.007_bib0036","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1182\/blood.V90.7.2747","article-title":"Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2","volume":"90","author":"Larson","year":"1997","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2023.01.007_bib0037","first-page":"64","article-title":"All trans retinoic acid treatment for patients with acute promyelocytic leukemia","volume":"6","author":"Fenaux","year":"1992","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jcyt.2023.01.007_bib0038","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/00002018-199818040-00003","article-title":"Retinoic acid syndrome. Recognition, prevention and management","volume":"18","author":"Fenaux","year":"1998","journal-title":"Drug safety"},{"issue":"2","key":"10.1016\/j.jcyt.2023.01.007_bib0039","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/bjh.16151","article-title":"Differentiation syndrome in acute promyelocytic leukaemia","volume":"187","author":"Stahl","year":"2019","journal-title":"British Journal of Haematology"},{"issue":"15","key":"10.1016\/j.jcyt.2023.01.007_bib0040","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199710093371501","article-title":"All-trans-retinoic acid in acute promyelocytic leukemia","volume":"337","author":"Tallman","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.jcyt.2023.01.007_bib0041","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.thromres.2004.11.001","article-title":"Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients","volume":"116","author":"Dally","year":"2005","journal-title":"Thrombosis research"},{"issue":"5","key":"10.1016\/j.jcyt.2023.01.007_bib0042","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3324\/haematol.2009.017962","article-title":"Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation","volume":"95","author":"Massimo","year":"2010","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.jcyt.2023.01.007_bib0043","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1182\/blood-2016-10-747170","article-title":"Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era","volume":"129","author":"Mantha","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2023.01.007_bib0044","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.leu.2404377","article-title":"Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features","volume":"21","author":"Breccia","year":"2007","journal-title":"Leukemia"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923000270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923000270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:50:38Z","timestamp":1761443438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324923000270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1465324923000270"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.01.007","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of therapeutic leukapheresis in acute promyelocytic leukemia: A single-center retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}